David Comas
Luciano Milanesi
Jean Charles Sánchez
Juan Bueren
José Antonio Riancho
David Comas David Comas is the Head of the Human Genome Diversity Group at the Universitat Pompeu Fabra (UPF) in Barcelona and the Director of the Department of Experimental and Health Sciences at the UPF. He obtained his PhD in Biology (awarded with the "Premi Claustre de Doctors de la UB") at the University of Barcelona. After predoctoral and postdoctoral stays at the Zoologisches Institut (LMU, Munich), the Anthony Nolan Trust-Royal Free Hospital (London), and the Department of Forensic Medicine (University of Helsinki), studying human population genetics, he established his group at the CEXS-UPF thanks to a "Ramon y Cajal" position. He is now an associate professor at the UPF, member of the Institut de Biologia Evolutiva (IBE, CSIC-UPF) and awarded within the ICREA Academia program. His research is focused on the analysis of the genome diversity in human populations in order to define and quantify the processes that have modeled the present genomic variation in humans. His research has also been focused on the phenotypic consequences, including disease, of the present variation in humans.
Luciano Milanesi Luciano Milanesi is the Head of the Bioinformatics Group at National Research Council (CNR) - Institute of Biomedical Technology. He has been working and published since 1986 in the field of Bioinformatics and System Biology and Medical Informatics to develop new methods applied to the human genome analysis. He is Director the Flagship "InterOmics" project of the Ministry of Education, Universities and Research (Italy). He is actually involved in the Common Service ICT, of the BBMRI-ERIC a Biobanks and biomolecular research infrastructure European consortium; ELIXIR a distributed infrastructure for life life-science information and responsible for the Italian national node of INCF of the international non-profit organization devoted to advancing the field of Neuroinformatics. He is a founder of the Bioinformatics Italian Society (BITS) and System Biology for Health Society (SYSBIO-HEATH).
Jean Charles Sánchez Jean-Charles Sanchez is the Head of the Biomedical Proteomics Group at the BPRG at the Geneva University and director of the Proteomics Core Facility of the Faculty of Medicine. He has been working since 1989 in the field of proteomics. As a co-inventor of the proteome concept, he has soon evaluated the great impact proteomics could have in biomarker discovery. Since then, its efforts have been concentrated to this goal and important results have been obtained in various types of diseases such as stroke, neurodegenerative diseases and diabetes. All these results permit to develop new diagnostic, therapeutic and predictive tools. He is a founder of the Swiss Proteomics Society (SPS) and the European Proteomics Association (EuPA) and the Editor in Chief of Translational Proteomics.
Juan Bueren Juan Bueren is the Head of the Hematopoietic Innovative Therapies Division at the CIEMAT and the Centre for Biomedical Research on Rare Diseases (CIBERER), and Coordinator of the Advanced Therapies Unit CIEMAT/IIS at the Fundación Jiménez Díaz (UAM). Awards of Appreciation and Distinguished Service Award from the Fanconi Anemia Research Foundation (FARF). He is also former President of the Spanish Society for Gene and Cell Therapy (2011-2013), board member of the European Society for Gene and Cell Therapy and member of the Hematologic and Immunologic Gene and Cell Therapy Committee from the American Society for Gene and Cell Therapy. He has worked and published in recent years on topics related with hematopoietic stem cells, gene therapy and cell reprogramming.
José Antonio Riancho José Antonio Riancho, MD, PhD, is Professor at the Universidad de Cantabria, Head of the Internal Medicine Department at the Hospital Universitario Marqués de Valdecilla and Researcher at the Instituto de Investigación Sanitaria Valdecilla, IDIVAL. His main research lines are related to the pathophysiologic mechanisms of prevalent skeletal disorders, and particularly the genomics of osteopososis and osteoarthritis. In recent years, he has focused on the role of epigenetic mechanisms in bone biology and the pathogenesis of bone disorders, being particularly interested in exploring the role of DNA methylation in the differentiation of the bone forming osteoblasts.